{"id":537832,"date":"2010-04-21T14:43:41","date_gmt":"2010-04-21T18:43:41","guid":{"rendered":"http:\/\/www.technologytransfertactics.com\/content\/?p=6388"},"modified":"2010-04-21T14:43:41","modified_gmt":"2010-04-21T18:43:41","slug":"queen-mary-spinouts-advance-through-sale-licensing-agreement","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/537832","title":{"rendered":"Queen Mary spinouts advance through sale, licensing agreement"},"content":{"rendered":"<p>ApaTech, a spinout from Queen Mary, University of London (QMUL) that was established in 2001 to manufacture and market synthetic bone substitutes, has been acquired by Deerfield, IL-based Baxter International, Inc., in an agreement valued at up to $330 million. ApaTech was launched at QMUL&#8217;s Interdisciplinary Research Centre in Biomedical Materials nine years ago with an initial investment of \u00a33 million. QMUL&#8217;s equity interest in the spinout means the college is set to receive a significant sum from the sale. ApaTech generated sales of approximately $60 million during 2009. Its lead product, Actifuse, is being used in Europe, the United States, and other markets around the world. The acquisition follows a number of successful VC investment rounds that fueled significant expansion of the business, including new manufacturing capacity, and enabled the company to continue the development of its lead products.<\/p>\n<p>&#8220;ApaTech is the perfect university spinout success story,&#8221; says Caroline Quest, managing director of Queen Mary Innovation (QMI), which serves as the TTO for QMUL and manages the equity interests in its spinout portfolio. &#8220;This sale demonstrates just how much can be achieved in a relatively short time frame when innovative scientists join together with top-class commercial leadership.&#8221;<\/p>\n<p>In another win for QMUL, Activiomics, Ltd. &#8212; the first spinout created from the Institute of Cancer at Barts and The London Medical School &#8212; has signed a commercial agreement with GlaxoSmithKline (GSK) through its Respiratory Centre of Excellence for Drug Discovery (CEDD) in a collaborative effort to investigate inflammatory signaling mechanisms. Scientists from Barts and The London School of Medicine and Dentistry at QMUL developed a novel method based on mass spectrometry to analyze and interpret cell signaling pathways. The technology enables the pharmaceutical and biotechnology industry to identify biomarkers and better select new drugs for diseases such as cancer, autoimmunity, and diabetes.<\/p>\n<p>The targeted in-depth quantification of cell signaling (TIQUAS) platform has several advantages over existing methods: it is quantitative, antibody-free, label-free, and applicable to any cell or tissue sample. These features offer significant value in reducing drug development cycle by aiding clinical trial candidate selection and biomarker discovery. Activiomics Ltd received early-stage financing from IP Group plc &#8212; the IP commercialization company that works closely with QMI to identify and develop new business opportunities from QMUL research. Sources: <a href=\"http:\/\/www.qmul.ac.uk\/media\/news\/items\/27498.html\" >Queen Mary University of London<\/a> and <a href=\"http:\/\/www.prlog.org\/10624713-activiomics-new-spin-out-from-queen-mary-university-of-london-signs-commercial-agreement-with-gsk.html\" >PRLog<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ApaTech, a spinout from Queen Mary, University of London (QMUL) that was established in 2001 to manufacture and market synthetic bone substitutes, has been acquired by Deerfield, IL-based Baxter International, Inc., in an agreement valued at up to $330 million. ApaTech was launched at QMUL&#8217;s Interdisciplinary Research Centre in Biomedical Materials nine years ago with [&hellip;]<\/p>\n","protected":false},"author":67,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-537832","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/537832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=537832"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/537832\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=537832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=537832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=537832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}